close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

12.69 -0.17 (-1.32%)
Streaming Delayed Price Updated: 1:05 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
News headline image
Why Stealth BioTherapeutics Shares Are Surging Today? ↗
 
Via Benzinga
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
News headline image
Expert Ratings For Amylyx Pharmaceuticals ↗
Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings: 
Via Benzinga
News headline image
FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success ↗
An advisory committee of the  
Via Benzinga
News headline image
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate ↗
The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035... 
Via Benzinga
News headline image
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning ↗
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine. 
Via InvestorPlace
News headline image
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump ↗
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
News headline image
40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
News headline image
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today? ↗
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA). 
Via InvestorPlace
News headline image
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. 
Via Benzinga
News headline image
Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug ↗
The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed. 
Via Investor's Business Daily
News headline image
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today ↗
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 ↗
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
92 Biggest Movers From Friday ↗
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest ↗
One analyst says Reata only has a 50% chance in a neurodegenerative disease. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today